Hong Kong Stock Announcement Highlights | Sanhua Intelligent Controls Issues Profit Alert with Expected Annual Net Profit Growth of 25%-50%

Stock News12-22 23:05

**Key Developments**: - SIMCERE PHARMA (02096) subsidiary signed an exclusive licensing agreement with Ipsen for SIM0613 (LRRC15 antibody-drug conjugate). - CloudMinds (09678) launched the medical expert large-scale model "ShanHai·ZhiYi 5.0". - China Innovation Investment (00564) plans to establish Zhongchuang Zhiling (Zhengzhou) Industrial Investment Partnership for external investment activities. - BrainAct (06681) participated in a national key R&D project and was approved as a Beijing Key Laboratory for Cognitive Impairment Digital Therapeutics. - DeepTech (01384) entered into a strategic cooperation agreement with Moore Threads. - Shimao Services (00873) intends to form a partnership with Huludao Yongsheng.

**IPO Updates**: - Hansoh Biotech (03378) saw its Hong Kong public offering oversubscribed by 3,074.09x, with an issue price of HK$32 per share. - EasyHealth (02661) recorded 1,421.47x oversubscription for its Hong Kong public offering, priced at HK$22.68 per share. - NobiCart (02635) achieved 188.74x oversubscription for its Hong Kong public offering, priced at HK$80 per share.

**Operational Performance**: - SANHUA (02050) issued a profit alert, expecting annual attributable net profit to rise 25%-50% YoY. - CATHAY PAC AIR (00293) carried 2.53 million passengers in November, up 26% YoY. - Top Sports (06110) reported a high single-digit decline in total Q3 retail and wholesale sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment